To assess health care utilisation for patients co-infected with TB and HIV (TB-HIV), and to develop a weighted health care index (HCI) score based on commonly used interventions and compare it with patient outcome. 
TUBERCULOSIS (TB) in human immunodefi ciency virus (HIV) positive persons remains a great challenge for physicians globally. Survival rates of HIV-positive persons with active TB (TB-HIV patients) vary substantially around the world and depend on several factors relating to the management of both HIV infection and TB disease. Among such factors, the most important are prompt and proper diagnosis of TB, including culture and drug susceptibility testing (DST), timely initiation of adequate anti-tuberculosis treatment, as well as assessment of a patient's immune status and timely initiation of combination antiretroviral treatment (cART). 1, 2 These factors are mainly related to, and depend on, the local level of health care and the availability of resources. Incidence rates of TB among HIV-infected persons would naturally be higher in regions with a high prevalence of Mycobacterium tuberculosis infection in the general population, while mortality rates are likely to be higher in settings with a high prevalence of multidrug-resistant
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199 TB (MDR-TB). [3] [4] [5] [6] [7] However, even in resource-limited settings with a high prevalence of TB it is possible to achieve a signifi cant reduction in TB-associated mortality among TB-HIV patients. 8, 9 We previously reported that a number of patient characteristics related to both HIV (i.e., acquired immune-defi ciency syndrome [AIDS] or poor immune status) and TB (i.e., disseminated or rifamycinresistant disease) were associated with an increased risk of death. In addition, some aspects related to patient care, such as not including a rifamycin in fi rstline anti-tuberculosis treatment or not commencing cART, were independent predictors of death. 6 These factors, however, could only partially explain regional differences in mortality, suggesting that other patient or health care-associated factors may differ between the geographic regions.
The purpose of the current analysis was to evaluate the extent of appropriate health care provided to TB-HIV patients across different geographic regions by establishing a health care index (HCI), and to use this HCI to generate a TB-HIV HCI score that refl ects health care utilisation. We then analysed the cumulative probability of death in patients stratifi ed by HCI score and regional differences in hazards of death in multivariable models incorporating the HCI score.
METHODS

Patient cohort
The TB-HIV study is an international cohort of HIVpositive patients consecutively diagnosed with TB who initiated anti-tuberculosis treatment between January 2004 and December 2006 at one of the 52 participating clinics in Europe and Argentina. The present analysis is based on 1061 TB-HIV patients whose HIV infection was diagnosed before or up to 1 month after TB diagnosis, to avoid bias when assessing HIV management. Details of the study have been published elsewhere. 6 Briefl y, information was collected retrospectively on standardised case report forms (CRF), and included demographic and clinical characteristics of the TB disease, details of smear tests, culture and DST performed, drug regimens used and TB outcomes. Information on underlying HIV infection was collected on a separate CRF, and included all available CD4 cell count and HIV-RNA measurements, use of antiretroviral drugs, presence of non-TB AIDSdefi ning illnesses and use of chemoprophylaxis. 10 The study was approved by the ethics committees of the participating clinics, as per local and national regulations. Patients had to sign informed consent where requested by local regulations.
Health care index
To evaluate aspects of TB and HIV health care, we chose a number of the most important health care parameters that refl ected the actual care provided to patients rather than disease-specifi c characteristics (e.g., 'having a culture or DST performed' rather than 'having MDR-TB'). These parameters were combined in an HCI, for which the following components were a priori considered to be based on the guidelines for management of TB-HIV patients: 1, 2 1 World Health Organization (WHO) defi ned definite diagnosis of TB: culture-confi rmed disease due to M. tuberculosis and/or at least one sputum smear examination positive for acid-fast bacilli (AFB); 11 2 Performance of DST for M. tuberculosis; 3 Inclusion of a rifamycin (R), isoniazid (H, INH) and pyrazinamide (Z, PZA) in the initial antituberculosis treatment regimen; 4 Availability of at least one CD4 cell count measurement between 6 months before and 1 month after TB diagnosis; 5 Initiation of cART (a combination of at least three antiretroviral drugs from any class) before or up to 1 month after TB diagnosis.
The 1-month cut-off for CD4 cell counts and use of cART was chosen to reduce survival bias, as substantial early mortality was observed. In sensitivity analyses, we assessed the effects of initiation of cART within 3, 6, 3-9 and >9 months of TB diagnosis, and CD4 cell count measurements obtained within 2, 3 and 6 months of TB diagnosis.
Statistical analysis
The study population was divided into four geographic regions according to country of residence: Eastern Europe (n = 573), Central/Northern Europe (n = 166), Southern Europe (n = 208) and Argentina (n = 114).* Descriptive statistics were used to compare patient characteristics and the HCI components across regions. The HCI components were considered as quantitative discrete variables (yes/no), and were given a score of zero if no information was available for a given patient. The proportion of patients to whom each HCI component applied was calculated and compared by region. Follow-up was from the date of TB diagnosis until the last clinic visit (or date of loss to follow-up), date of death or 1 year after TB diagnosis, whichever occurred fi rst. TB was classifi ed as pulmonary if disease was limited to the lungs and/or pleura; extra-pulmonary if TB was limited to any other single organ system; or disseminated if it was miliary TB, TB in at least two organ systems, or if M. tuberculosis had been isolated from blood or bone marrow.
To establish an HCI score, the relative hazard (RH) of death for each HCI component was calculated using a multivariable Cox model incorporating all fi ve HCI components. A weighted score was then 200 The International Journal of Tuberculosis and Lung Disease assigned to each signifi cant HCI component based on the natural logarithm of its RH of death. The mean HCI score was calculated for each region and compared to the proportion of patients who died within 12 months of TB diagnosis and to those with successful TB outcomes (cure/treatment completion).
Kaplan-Meier survival analysis was used to estimate the probability of death within 12 months of TB diagnosis among patients stratifi ed by HCI score. Cox proportional hazard models were used to analyse the effect of the HCI score on mortality. Other factors included in the Cox model were those that were previously shown to be associated with mortality, and included sex, CD4 cell count at TB diagnosis, previous AIDS diagnosis, previous TB diagnosis, TB rifamycin resistance and site of TB. 6 
RESULTS
Patient population
A total of 1061 TB-HIV patients were included in the analysis. Patient characteristics are presented in Table 1. As reported previously, patients from Eastern Europe were younger and more often had a history of injection drug use (IDU) and/or hepatitis C coinfection. 6 Approximately half of all patients had disseminated TB, and the majority of patients had established HIV infection at the time of TB diagnosis. Patients from Argentina had more profound immunodefi ciency, while patients from Eastern Europe had less advanced HIV infection.
The proportion of patients with positive values for each HCI component differed signifi cantly by geographic region (Table 1) . Fewer patients in Eastern Europe had a defi nite TB diagnosis, initiated RHZcontaining anti-tuberculosis treatment or received cART. Patients in Eastern Europe and Argentina were less likely to undergo DST for M. tuberculosis and have CD4 cell counts performed.
Health care index score
To develop an HCI score, the fi ve selected components were included in a Cox model, with death as the dependent variable ( Table 2) . Use of cART, RHZcontaining initial anti-tuberculosis treatment and undergoing DST were associated with a reduced hazard of death in both univariable and multivariable models. The availability of a CD4 cell count and a defi nite TB . TB = tuberculosis; HIV = human immunodeficiency virus; IDU = injection drug use; AIDS = acquired immune-deficiency syndrome; IQR = interquartile range; DST = drug susceptibility testing; RHZ = rifamycin+isoniazid+pyrazinamide; cART = combination antiretroviral therapy; HCV = hepatitis C virus.
diagnosis were not associated with a reduced hazard of death in either univariable or multivariable analysis (Table 2 ). These two components were therefore not included in the fi nal HCI score. Similar results were obtained when using different time windows for CD4 cell count measurements or cART initiation (data not shown). Of note, having a culture-based defi nitive TB diagnosis (i.e., excluding patients with only positive smear tests) was highly correlated with undergoing DST (R = 82%, P < 0.0001). Including smearpositive tests in the defi nitive diagnosis reduced this correlation to 62%, and reduced the association between defi nitive diagnosis and the risk of death to a non-insignifi cant level. The natural logarithms of the three RHs of death were used to weigh the components that make up the HCI score. As the effects of initial treatment with RHZ and use of cART were approximately double the magnitude of the effect of DST, DST was assigned 1 point and the use of RHZ-containing initial antituberculosis treatment and use of cART 2 points each. The HCI score could thus range from 0 to 5, with a higher score being indicative of more intensive health care utilisation (Table 2 ).
An HCI score was calculated for each patient. The distribution of HCI scores for each region is shown in Figure 1 . The majority (54-82%) of patients from Central/Northern Europe, Southern Europe and Argentina had HCI scores ⩾3, compared with only 29% of patients from Eastern Europe (P < 0.0001), whereas 28% of those in Eastern Europe had an HCI score of 0. The mean HCI score was highest in Central/Northern Europe (3.2, 95% confi dence interval [CI] 3.1-3.3), followed by Southern Europe 202 The International Journal of Tuberculosis and Lung Disease (3.0, 95%CI 2.9-3.2) and Argentina (2.9, 95%CI 2.6-3.0); it was lowest in Eastern Europe (1.6, 95%CI 1.5-1.7, P < 0.0001).
Health care index score and anti-tuberculosis treatment outcome
Information on treatment outcome was available for 995 (98%) patients. Overall, a successful treatment outcome was reported for 578 patients (58%), and was most common in those regions with the highest HCI scores. Similarly, Kaplan-Meier estimates of being alive at 12 months were highest in regions with the highest HCI scores (Figure 2 ). A progressive decrease was observed in 12-month cumulative mortality, from 39% (95%CI 31-48) for patients with HCI = 0, to 9% (95%CI 6-13) for those with HCI ⩾ 4 (P < 0.0001; Figure 3 ). When the HCI score was incorporated into unadjusted Cox models of death within 12 months of TB diagnosis, a 38% decrease in mortality for each unit increase in HCI score was observed (RH 0.62, 95%CI 0.56-0.70, P < 0.0001; Table 3 ). This association remained signifi cant (RH 0.73, 95%CI 0.64-0.84) after adjustment for other factors that could potentially affect the prognosis of TB-HIV patients (sex, CD4 cell count at TB diagnosis, previous TB or AIDS diagnosis, rifamycin resistance and site of TB; Table 3 ). However, despite the signifi cant predictive value of the HCI score, patients from Eastern Europe remained at an approximately three-fold increased risk of death compared with the other regions, after adjustment for HCI score.
Sensitivity analyses
A number of sensitivity analyses were performed (Table 3) to test the performance of the score in various subpopulations. Overall, the results of these analyses were consistent with the main fi nding that the HCI score was a signifi cant predictor of 1-year mortality in TB-HIV patients. For example, when restricting the analysis to IDU patients (n = 521) or patients from Eastern Europe (n = 573), a 1-unit increase in HCI score was associated with respectively 24% and 27% decreases in mortality. In analysis restricted to patients with pan-susceptible TB (n = 337), a 1-unit increase in HCI score was associated with a 27% decrease in mortality, although this was insignifi cant in the multivariable model, likely due to the small sample size. Furthermore, when restricting endpoints to only TB-and AIDS-related deaths (excluding deaths from any other causes), a 1-unit increase in HCI score reduced mortality by 15%. Finally, when the HCI score was included in the model as a categorical variable, 1-year mortality was 45% lower in patients with an HCI score of 1 and 72% lower in those with HCI scores of 4/5 compared with patients with an HCI score of 0 (Table 3) .
DISCUSSION
In this study, we assessed and compared health care utilisation for TB-HIV patients by using a number of health care parameters. These parameters were further used to generate an HCI score as a measure of health care utilisation. The fi nal HCI score, which was based on the use of TB DST, RHZ-based antituberculosis treatment and early cART, was predictive of mortality in TB-HIV patients: a 1-unit increase was independently associated with a 27% reduced risk of death within the fi rst year of TB diagnosis. However, the observed regional differences in mortality among TB-HIV patients in Europe and Argentina were only partly explained by differences in health care utilisation. While implementation of the health care parameters included in the HCI score would be a priority to improve patient outcome, further research is required to explain the profound regional differences in HIV and TB outcomes and propose additional measures to harmonise these outcomes. The HCI score presented here can be implemented and used for two main purposes: evaluating and comparing health care utilisation for TB-HIV patients, and predicting patients' prognosis. It can be implemented and assessed by health care authorities at various levels, from a single clinic to programme, country and region. Further, it can contribute to the establishment of a benchmark of health care utilisation for TB-HIV patients by identifying a best performing facility. The advantage of this HCI score is that it includes a set of three simple, widely used diagnostic and treatment procedures, which should be available in both highand low-income settings. Our HCI score is based on health care parameters that have previously been found to be independently associated with the outcome of TB-HIV patients. 5, 6, 12 The predictive value of the HCI score remained highly signifi cant when the model was adjusted for other factors that might play a role in patient outcome ( Table 3 ), suggesting that this association is not a result of confounding. Optimal management of TB includes early case detection and initiation of effective anti-tuberculosis treatment. Increased frequency of sputum smear negativity in HIV patients requires culture, which has been shown to be more sensitive in TB-HIV patients. 13, 14 Culture and DST are essential in TB diagnosis to ensure that effective treatment is administered, particularly in settings with high MDR-TB prevalence. 15, 16 Conventional culture and DST are disadvantaged by the need for sophisticated laboratory equipment and long incubation time. Early detection of resistant M. tuberculosis strains is critical, particularly in high MDR-TB prevalent settings, to adjust treatment regimens and prevent transmission of drugresistant strains. There is thus a critical need for the diagnosis of TB to be more rapid and reliable and less costly than is currently the case in many resourcelimited settings. [17] [18] [19] Rapid tests for simultaneous molecular detection of M. tuberculosis and drug-resistant strains should be widely implemented and used. 17 As approximately 50% of our patients had disseminated TB, relying solely on sputum samples may not be suffi cient to make a defi nite TB diagnosis, and culture or molecular diagnostics of lymph node aspirates, blood or bone marrow may need to be more widely undertaken to obtain M. tuberculosis isolates for DST, thus fulfi lling this HCI component. 20, 21 Successful outcome of anti-tuberculosis treatment relies on a treatment regimen of high-quality drugs to which the M. tuberculosis isolate is susceptible, given at the correct dose and for a suffi cient duration. 1, 21 The WHO recommends that empiric anti-tuberculosis treatment should include at least a rifamycin, INH and PZA (i.e., RHZ-based), with the addition of 2-3 second-line anti-tuberculosis drugs if resistance is suspected. 22 When the DST results become available, the regimen should be adjusted accordingly. In our study, the use of RHZ-based regimens as initial TB treatment and outcome were strongly correlated, even after adjustment for region of residence. 6 While this may refl ect clinicians' decisions to avoid RHZ in patients with poor outcome, such as those with signifi cant liver injury (i.e., hepatitis C virus co-infected), 23 universal implementation of RHZ-based regimens to treat TB-HIV in Eastern Europe is an inexpensive measure to improve patient outcome. More importantly, if second-line anti-tuberculosis drugs are added while awaiting the DST results, amplifi cation of TB drug resistance in partially resistant M. tuberculosis isolates may be avoided and transmission of drug-resistant TB reduced. Further research is needed to investigate underlying reasons for not initiating RHZ-based treatment in Eastern Europe.
Three recent studies have addressed the timing of cART in TB-HIV patients. [24] [25] [26] [27] Both studies provided evidence for early cART initiation in patients with CD4 cell counts < 50 cells/mm 3 . In addition, the SAPiT (Starting ART at 3 Points in TB) study showed benefi t from cART use during treatment rather than deferral until completion of anti-tuberculosis treatment, even in patients with CD4 cell counts > 200 cells/mm 3 .
We observed that few patients were receiving cART before TB diagnosis or up to 1 month after TB diagnosis, irrespective of region of residence, and many of our patients did not commence cART during antituberculosis treatment. Our HCI model suggests that there are benefi ts from early cART use in TB-HIV patients, which is consistent with the results of the above clinical trials and provides support for the notion that all TB-HIV patients should start cART while still receiving anti-tuberculosis treatment. For most patients, cART may be safely deferred until the end of the intensive phase of anti-tuberculosis treatment, although patients with low CD4 cell counts or other evidence of immunosuppression, and possibly those infected with MDR-TB, should start cART at the earliest opportunity (i.e., within 2 weeks of starting antituberculosis treatment). 25, 26 In Eastern Europe especially, this will require improved access to cART for marginal population groups (i.e., IDUs, prisoners, alcohol addicts, etc.) and adherence support for those who start cART. 28 Finally, when making the decision to initiate cART in TB-HIV patients, the benefi ts and risks should be carefully weighed for each individual patient, considering the potential toxicities and drugdrug interactions, the probability of immune reconstitution infl ammatory syndrome, adherence issues, etc. There are some limitations to this study. Due to the retrospective design, some data could have been missed or were not available for collection. To ensure the completeness of data collection, an extensive quality assurance programme was performed, which included queries to the sites and monitoring visits. We were able to defi ne the HCI score using variables measured within the study; however, there may be other variables that we were not able to capture. Although we included health care parameters known to be associated with patient outcome, 5, 6, 12 other factors, including prevalence of primary MDR-TB, use of second-line anti-tuberculosis drugs, presence of integrated HIV and TB services, etc., may affect outcomes. Future studies designed around these factors are needed to enable measures to be identifi ed that may further improve TB-HIV outcomes, particularly in Eastern Europe. Experience from South Africa has shown that integration of HIV and TB services helps to improve patient management, and thus survival. 29 Health care infrastructure differs in Eastern Europe, and is characterised by separate management of HIV and TB in different hospitals by different specialists, where collaboration and data exchange may not be well developed. A sensitivity analysis including only patients from Eastern Europe showed results consistent with the main analysis: a higher HCI score was associated with improved survival. The HCI score also did not change when the models were stratifi ed by an individual centre or country (data not shown). The HCI score needs to be validated in independent cohorts of TB-HIV patients in Europe and elsewhere, including low-income countries. Validation of the HCI score is also planned in a prospective extension of the TB-HIV study, which has now been initiated (http://www.cphiv.dk).
Based on our HCI score, and in line with previous publications, TB-HIV programmes in the developing world are encouraged to implement DST, standard anti-tuberculosis treatment and early cART initiation in TB-HIV patients. 30 The HCI score presented here may serve as a tool to predict the benefi ts of such interventions. Further refi nement of the health care parameters, for example by adding additional components, such as TB-HIV service integration, duration of anti-tuberculosis treatment, treatment changes according to DST patterns, use of directly observed treatment, use of cotrimoxazole prophylaxis and treatment adherence, may enhance its clinical usefulness.
CONCLUSIONS
We have developed an HCI score that refl ects health care utilisation in TB-HIV patients and predicts outcome. The HCI is easy to apply in both high-and low-income settings and, if validated in other populations, may assist in the planning of programmatic interventions. Our results suggest that the outcome of TB-HIV patients may be improved by implementing several simple measures, including M. tuberculosis DST, use of RHZ-based anti-tuberculosis treatment and early use of cART.
